
Download the app to access in-depth Shariah compliance reports for over 60,000 global stocks.
Get the App
Equillium, a clinical-stage biotechnology company, develops products to treat severe autoimmune and inflammatory disorders. Its lead product candidate, itolizumab (EQ001), a monoclonal antibody targeting CD6, is in Phase III trials for acute graft-versus-host disease and has completed Phase Ib trials for asthma and lupus nephritis. The company also develops EQ101 for cutaneous T cell lymphoma and alopecia areata, and EQ102 for gastrointestinal diseases.